

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MEDICAL SYSTEM HOLDINGS LIMITED

康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 867)

Voluntary and Business Update Announcement

Positive Results for Tildrakizumab Phase III Clinical Trial in China

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s innovative drug Tildrakizumab solution for injection (the “Product”) obtained positive results of its Phase III clinical trial in China (the “Trial”).

The Trial is a randomized, double-blind, placebo-controlled, multi-centre clinical trial, with 220 patients enrolled in total, aiming to evaluate the safety and efficacy of the Product for treatment of patients among the Chinese population with moderate-to-severe plaque psoriasis.

The preliminary trial results demonstrated that comparing with placebo, the treatment of the Product for 12 weeks significantly increased the proportion of subjects who have achieved at least 75% of improvement in psoriasis area and severity index (PASI 75), which was vastly superior to placebo.

The Group will actively move forward the Product’s new drug application (NDA) in China.

About Tildrakizumab solution for injection

The Product is a humanized IgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. The

Product has been approved for marketing in the U.S., Europe, Australia and Japan for treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Psoriasis is an autoimmune disease with complex causes, whereas IL-23 is regarded as one of important driving factors in the pathogenesis of it. There are more than 6.5 million people suffering from psoriasis in China with an incidence rate of 0.47%. About 30% of patients are with moderate-to-severe psoriasis, among them, nearly 62% are dissatisfied with existing treatment options. Tildrakizumab solution for injection is expected to be a safe, effective and the most cost-effective innovative monoclonal antibody targeting IL-23, benefiting more patients and their families in China.

The announcement is made on a voluntary basis by the Company. Shareholders and investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 21 July 2021

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive Directors; and (ii) Mr. Wu Chi Keung, Mr. Leung Chong Shun and Ms. Luo, Laura Ying as independent non-executive Directors.